Skip to main content
Explore URMC

menu

Lymphoma (DLBCL): A Study Comparing the Efficacy & Safety of Polatuzumab Vedotin w/ Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone in Diffuse Large B-Cell Lymphoma (POLARIX)

Research Question:
What are the good and bad effects of polatuzumab vedotin in combination with four other drugs, rituximab (R) (also known as Rituxan® and MabThera®), cyclophosphamide (C), doxorubicin (H), and prednisone (P) (when given together, referred to as R-CHP) compared with vincristine (O) in combination with R-CHP (referred to as R-CHOP) on you and your lymphoma and which treatment is better?

Basic Study Information

Purpose:
If you decide to participate in this study you will be randomly assigned by a computer program to one of the following treatment groups: polatuzumab vedotin and R-CHP with placebo, or R-CHOP with placebo. Since the difference between the treatment groups is polatuzumab vedotin in one group and vincristine (O) in the other, both groups will receive a placebo, which is a substance that looks like either polatuzumab vedotin or vincristine but contains no active medication. Neither you nor your study doctor may choose the group that you will be in. You will have an equal chance of being placed in either group. Neither you nor your study doctor will know which treatment you receive.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03274492?term=go39942&rank=1
Study Reference #: ILYM17113

Lead Researcher (Principal Investigator)

Lead Researcher: Patrick Reagan

Study Contact Information

Study Coordinator: Krista French
Phone: (585) 276-5812
Email: Krista_French@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoma

Return to Search